ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Simple Search Results

Didn't find what you were looking for? Try the Advanced Search »

  • 1
  • 2
  • 3
  • …
  • 17
  • Next Page »
Search Again »
  • Abstract Number: 0379 • ACR Convergence 2024

    Effectiveness and Safety of Baricitinib for the Treatment of Juvenile Idiopathic Arthritis Associated Uveitis or Chronic Anterior Antinuclear Antibody Positive Uveitis in Children

    Athimalaipet Ramanan1, Catherine Guly2, Gabriele Simonini3, Stuart Keller4, Priyanka Sen4, Thorsten Holzkaemper4 and PIERRE QUARTIER5, 1Bristol Royal Hosp for Children, Bristol, United Kingdom, 2University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom, 3Meyer Children’s Hospital IRCCS; University of Florence, Florence, Toscana, Italy, 4Eli Lilly and Company, Indianapolis, IN, 5Université Paris-Cite, IMAGINE Institute, Necker Children’s Hospital, Paris Cedex 15, France

    Background/Purpose: Baricitinib could target multiple cytokine pathways associated with juvenile idiopathic arthritis associated uveitis (JIA-U) and antinuclear antibody (ANA)-positive uveitis, providing a novel therapeutic approach.…
  • Abstract Number: 0476 • ACR Convergence 2024

    Baricitinib in Rheumatoid Arthritis – Interstitial Lung Disease. National Multicenter Study of 72 Patients

    Ana Serrano-Combarro1, Belén Atienza-Mateo2, Jesús Alejandro Valero Jaimes3, Marta Pastor-Mena4, Rafael Benito Melero-Gonzalez5, María Martín López6, Santos Castañeda7, Jesús Loarce8, César Antonio Egües Dubuc9, Natalia Mena Vázquez10, Carmen Carrasco-Cubero11, Carolina Perez-Garcia12, Juan M Blanco Madrigal13, Nuria Vegas Revenga14, Lorena Pérez Albadalejo15, Rafaela Ortega-Castro16, Desiree Palma17, Ana Fernández-Ortiz18, Maria López Lasanta19, Marta Garijo Bufort20, Ivette Casafont-Sole21, Andrea García-Valle22, Maria Paz Martinez-Vidal23, Bryan Josué Flores Robles24, EVELIN CERVANTES PEREZ25, Ignacio Brana Abascal26, Sara María Rojas Herrera27, Juan Camilo Sarmiento-Monroy28, Virginia Ruiz-Esquide29, JOSE RAMON LAMUA RIAZUELO30, Uxue Astigarraga-Urquia31, Diego Ferrer32 and Ricardo Blanco-Alonso33, 1Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, 2Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, 3Zumarraga Hospital, Zumarraga, Spain, 4Hospital de Jeréz de la Frontera, Cadiz, Spain, 5CHU Ourense, O Carballino, Spain, 6General University Hospital of Ciudad Real, Ciudad de México, Spain, 7Hospital Universitario de la Princesa, Madrid, Spain, 8Ramón y Cajal University Hospital, Madrid, Madrid, Spain, 9Hospital Universitario de Donostia, Donostia, Pais Vasco, Spain, 10IBIMA, Málaga, Andalucia, Spain, 11Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, 12Hospital del Mar, Barcelona, Spain, 13BASURTO UNIVERSITY HOSPITAL, Bilbao, Spain, 14Hospital Galdakao- Usansolo, Galdakao, Spain, 15Hospital Universitario de Jaén, Jaén, Spain, 16Hospital Reina Sofía, Cordoba, Andalucia, Spain, 17Hospital Rafael Méndez, Lorca, Murcia, Spain, 18Hospital Universitario de Badajoz, Badajoz, Spain, 19Hospital Vall d�Hebron, Barcelona, Spain, 20Hospital de Sagunto, Valencia, Spain, 21Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 22Hospital General Río Carrión, Palencia, Spain, 23Hospital San Juan de Alicante, Alicante, Spain, 24Hospital San Pedro, Logroño, Spain, 25Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Galicia, Spain, 26Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain, 27Hospital de Mérida, Badajoz, Spain, 28Hospital Clínic Barcelona, Barcelona, Spain, 29Hospital Clinic de Barcelona, Barcelona, Spain, 30Hospital Universitario del Henares, Madrid, Spain, 31Hospital Universitario de Navarra, Pamplona, Spain, 32Division of Pneumology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 33Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: Interstitial lung disease (ILD) is a severe extraarticular manifestation of rheumatoid arthritis (RA) that determines a worse prognosis, leading the cause of mortality in RA…
  • Abstract Number: 0507 • ACR Convergence 2024

    Neutrophil Activation Markers Can Predict Rheumatoid Arthritis Treatment Response to the Janus Kinase 1/2 Inhibitor Baricitinib

    Runa Kuley1, Bhargavi Duvvuri1, Sabeeha Hasnain2, Ernst Dow3, Alisa Koch4, Richard Higgs4, Venkatesh Krishnan4 and Christian Lood5, 1University of Washington, Seattle, 2Mahindra University, Hyderabad, India, 3Eli Lilly and Co, Indianapolis, IN, 4Eli Lilly, Indianapolis, IN, 5University of Washington, Seattle, WA

    Background/Purpose: Neutrophils play an important role in regulating immune and inflammatory responses in rheumatoid arthritis (RA). We assessed whether baricitinib, a JAK1/JAK2 inhibitor, could reduce…
  • Abstract Number: 0522 • ACR Convergence 2024

    Hematological Impact Assessment of Tofacitinib, Baricitinib, and Upadacitinib in Rheumatoid Arthritis Treatment

    Soo Min Ahn, Mi-Ra Cho, Ji Seon Oh, Yong-Gil Kim, Chang-Keun Lee, Bin Yoo and Seokchan Hong, Asan Medical Center, Seoul, Republic of Korea

    Background/Purpose: Janus kinase (JAK) inhibitors' introduction has significantly revolutionized the therapeutic landscape, notably influencing the management strategies for rheumatoid arthritis (RA). To compare the effects…
  • Abstract Number: 0858 • ACR Convergence 2024

    Baricitinib in Early Polymyalgia Rheumatica (BACHELOR Study)

    Alain SARAUX1, Guillermo CARVAJAL ALEGRIA2, Emmanuelle Dernis3, christian roux4, Christophe Richez5, Alice TISON6, Baptiste Quere7, Sandrine Jousse-Joulin8, Dewi Guellec7, Thierry Marhadou9, Patrice Kervarrec7, Divi Cornec10, Catherine Le Henaff7, Sandra Lesven7, nowak emmanuel7, Aghiles Souki7 and Valerie Devauchelle11, 1CHU Brest, Brest, France, 2CHRU de Tours, Tours, France, 3CH LE MANS, LE MANS, Pays de la Loire, France, 4rheumatology department, university Cote d'Azur, nice, France, 5Université de Bordeaux, Bordeaux, France, 6CHU de la Cavale Blanche, Brest, France, Brest, France, 7Centre Hospitalier Regional Universitaire (CHU) de Brest, Brest, France, 8cavale blanche hospital, brest, France, 9CHU Cavale Blanche, Brest, France, 10University of Brest, Brest, France, 11UBO, Brest, France

    Background/Purpose: Moderate glucocorticoids (GCs) improve nearly all cases of polymyalgia rheumatica (PMR) but related adverse events are common in senior patients.  The purpose of this…
  • Abstract Number: 1731 • ACR Convergence 2024

    Baricitinib in the Treatment of Adult Idiopathic Inflammatory Myopathy: A Randomized, Treatment Delayed-Start Clinical Trial

    hector Chinoy1, Ashma Krishan1, Yvonne Sylvestre1, James Lilleker2, Patrick Gordon3, Sarah Tansley4, Athiveeraramapandian Prabu5, Aamir Aslam6, Andrew Snedden7 and Janine Lamb8, 1The University of Manchester, Manchester, United Kingdom, 2Northern Care Alliance NHS Trust, Salford, United Kingdom, 3nhs, London, United Kingdom, 4University of Bath, Bath, United Kingdom, 5Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom, 6Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 7Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom, 8University of Manchester, UK, Manchester, United Kingdom

    Background/Purpose: The aim of the study was to assess the effects of baricitinib, a JAK1/2 inhibitor, following 24 weeks of active treatment on disease activity…
  • Abstract Number: 1959 • ACR Convergence 2024

    A 3-arm, Randomized, Open-label, Parallel Active Controlled, Multicentre International Study to Compare the Response of Ultrasound-assessed Synovitis to Baricitinib, Alone and Combined with Methotrexate versus Etanercept in Rheumatoid Arthritis Patients

    ESPERANZA NAREDO1, Otto Olivas-Vergara2, Pablo E. Borges2, Sheila Recuero-Díaz2, Fernando Saraiva3, Joana Martinho3, Filipa Costa3, Catarina Tenazinha3, Margarida Monteiro3, Ana Teresa Melo3, Ana Rodriguez-García4, Carlos A. Guillén-Astete5, Boris A. Blanco-Cáceres4, Alina L. Boteanu4, Antonio Mera-Varela6, Eva Pérez Pampín6, Yolanda López Golán6, Cristina Campos Fernández7, Jorge Juan Fragío Gíl7, roxana gonzalez mazarío7, Juan José De Agustín8, Gustavo Añez Sturchio9, Luis Coronel Tarancon8, Esther Vicente-rabaneda10, Santos Castañeda10, Irene Llorente-Cubas10, Maria S. Stoenoiu11, NZEUSSEU TOUKAP Adrien12, Ilaria Padovano13, Helene Gouze13, Ariane Leboime13, Maxime Breban14, Jaqueline Uson15, Virginia Villaverde16, Martina Steiner17, Cristina Vergara Dangond17, Maria Beatriz Paredes Romero17, Santiago Muñoz Fernández18, Carolina Pérez-García19, Juan Antonio Meraz-Ostiz19, Stephanie Finzel20, Anna-Maria Kanne21, Aránzazu Mediero22, Carmen Herencia23, Gabriel Herrero-Beaumont24 and Raquel Largo22, 1Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, 2Department of Rheumatology and Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD, Madrid, Spain, 3Rheumatology Department, Unidade Local de Saúde de Santa Maria. Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Lisbon, Portugal, 4Rheumatology Department. Ramón y Cajal University Hospital, Madrid, Spain, 5Rheumatology Department. Ramon y Cajal University Hospital, Madrid, Spain, 6Department of Rheumatology. Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain, 7Department of Rheumatology. Hospital General Universitario de Valencia, Valencia, Spain, 8Image and Technics Unit, Department of Rheumatology. Hospital Universitari Vall d’Hebron, Barcelona, Spain, 9Department of Rheumatology. Hospital Arnau de Vilanova, Lleida, Spain, 10Hospital Universitario de La Princesa, Madrid, Spain, 11Cliniques Universitaires Saint-Luc, Brussels, Belgium, 12Institut de Recherche Expérimentale et Clinique, Cliniques universitaires Saint-Luc, Université catholique de Louvain, St.-Lambrechts-Woluwe, Belgium, 13Departement of Rheumatology, Hopital Ambroise Paré, Boulogne-Billancourt, Spain, 14Departement of Rheumatology, Hopital Ambroise Paré, Departement of Rheumatology, Hopital Ambroise Paré, Spain, 15Department of Rheumatology, Hospital Universitario de Móstoles. University Rey Juan Carlos, Madrid, Spain, 16Department of Rheumatology, Hospital Universitario de Móstoles, Madrid, Spain, 17Department of Rheumatology. Hospital Universitario Infanta Sofía., Madrid, Spain, 18Hospital Universitario Infanta Sofía. Universidad Europea de Madrid, Madrid, Spain, 19Department of Rheumatology, Hospital del Mar of Barcelona, Barcelona, Spain, 20Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, Freiburg, DE, Freiburg im Breisgau, Germany, 21Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany, 22Joint and Bone Research Unit. IIS-Fundación Jiménez Díaz, Madrid, Spain, 23Joint and Bone Research Unit. IIS-Fundación Jiménez Díaz, M, Spain, 24Department of Rheumatology and Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain

    Background/Purpose: To demonstrate non-inferiority of the response of musculoskeletal ultrasound (MSKUS)-assessed synovitis to baricitinib, alone and plus MTX vs. etanercept plus MTX in patients with…
  • Abstract Number: 2245 • ACR Convergence 2024

    Clinical Efficacy and Molecular Cardiovascular Changes of Baricitinib in Biologic-naïve Patients with Rheumatoid Arthritis. Direct Comparative Analysis with TNF Inhibitors and Conventional DMARDs

    Chary Lopez-Pedrera1, Laura Muñoz-Barrera2, Rafaela Ortega-Castro3, Sagrario Corrales2, Jerusalén Calvo4, Concepción Aranda-Valera5, María Lourdes Ladehesa-Pineda1, Pilar Font2, Ismael Sánchez Pareja2, Elena Moreno-Caño5, María Carmen Ábalos-Aguilera6, Christian Merlo-Ruiz6, Mª Angeles Aguirre-Zamorano7, Tomás Cerdó2, Nuria Barbarroja2, Carlos Perez-Sanchez2 and Alejandro Escudero-Contreras2, 1IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, 2IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 3Hospital Reina Sofía, Cordoba, Andalucia, Spain, 4IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, 5IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Andalucia, Spain, 6IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Spain, 7IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Andalucia, Spain

    Background/Purpose: The main objective of this study was to conduct extensive clinical and molecular analyses to accurately characterize the specific effects of Baricitinib (4 mg/day)…
  • Abstract Number: 0450 • ACR Convergence 2023

    Baricitinib versus TNF-inhibitors in Patients with Active Rheumatoid Arthritis After Failure of CsDMARDs: A Pragmatic, Multicenter, Real-Life Study in a Treat-to-Target Setting

    Martinus Van de Laar1, Martijn Oude Voshaar1, Peter ten Klooster1, Danyta Tedjo2 and celine van de laar3, 1University of Twente, Hengelo (OV), Netherlands, 2TiH @ University of Twente, Hengelo (OV), Netherlands, 3Erasmus School of Health Policy and Management, Erasmus University, Rotterdam, Netherlands

    Background/Purpose: The EULAR guidelines for Rheumatoid Arthritis (RA) patients advise to use a strategy aiming at a predefined target of disease activity (T2T). If this…
  • Abstract Number: 0600 • ACR Convergence 2023

    Identification of Subsets of SLE Patients Responsive to Baricitinib by Transcriptomic Analysis at Baseline

    Prathyusha Bachali1, Amrie Grammer2 and Peter Lipsky2, 1AMPEL BioSolutions, Redmond, WA, 2AMPEL BioSolutions, Charlottesville, VA

    Background/Purpose: Baricitinib is an inhibitor of Jak1 approved for treatment of rheumatoid arthritis, atopic dermatitis, alopecia areata and Covid-19. A phase 2 trial showed success…
  • Abstract Number: 1167 • ACR Convergence 2023

    Transcriptome Analysis of Peripheral Blood Reveals Superiority of the Triple Combination of Baricitinib, Rituximab, and Tacrolimus Therapy (BRT-Tx.) for anti-MDA5 Antibody-positive Dermatomyositis (MDA5-DM)

    Yoshinobu Koyama1, Yoshiharu Sato2, Yu Nakai3 and Moe Tokunaga(Sakamoto)3, 1Japanese Red Cross Okayama Hospital, Okayama, Japan, 2DNA Chip Research Inc, Tokyo, Japan, 3Rheumatology, Center for Autoimmune diseases, Japanese Red Cross Okayama Hospital, Okayama, Japan

    Background/Purpose: MDA5-DM is characterized by high mortality due to rapid progressive ILD. We reported that in MDA-5DM, (1) RIG-1-like receptor signaling is enhanced, (2) antiviral…
  • Abstract Number: 1822 • ACR Convergence 2023

    The Food and Drug Administration’s (FDA’s) Safety Surveillance of Baricitinib and Tocilizumab for COVID-19 (Disclaimer: This Abstract Reflects the Views of the Authors and Not Necessarily Those of the US FDA)

    Laura Kangas1, Lisa Wolf2, Maya Beganovic3, Rachna Kapoor4, James Kidd4, Kate McCartan4, Kim Swank4 and Ida-Lina Diak4, 1Food and Drug Administration, Bethesda, MD, 2Food and Drug Administration, Chevy Chase, MD, 3Food and Drug Administration, Chicago, IL, 4Food and Drug Administration, Silver Spring, MD

    Background/Purpose: Baricitinib, a Janus kinase inhibitor, and tocilizumab, an interleukin-6 receptor antagonist, are two products first approved for the treatment of rheumatoid arthritis. Notably, these…
  • Abstract Number: 1823 • ACR Convergence 2023

    Higher Body Mass Index and Older Age, Both of Which Are Linked to Immunothrombosis Are Associated with Improved Survival with Baricitinib Therapy in COVID-19 Pneumonia

    Paula David1, Niv Ben-Shabbat2, Or Hen1, Howard Amital3, Abdulla watad4 and Dennis McGonagle5, 1University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), Leeds, United Kingdom, 2Department of Medicine 'B'. Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, 3Sheba Medical Center - Tel Hashomer, Ramat Gan, Israel, 4Sheba Medical Center, Ramat Gan, Israel, 5Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Immunothrombosis is a critical pathological feature of fulminant COVID-19 pneumonia in which immunosuppression with common immunomodulatory agents such as corticosteroids, IL-6 receptor blockers, and…
  • Abstract Number: 1963 • ACR Convergence 2023

    Effect of JAK-STAT Inhibition by Baricitinib and Tofacitinib on Disease Phenotype in a Mouse Model of Myositis

    Rita Spathis, Sabrina Narvesen, Deeva Robles Kuriplach, Karen Huang, Teja Sundar, Daniel Shulman, Elizabeth Bagley, Kanneboyina Nagaraju and Melissa Morales, Binghamton University, Johnson City, NY

    Background/Purpose: Dysregulation of the interferon (IFN) pathway plays a major role in the pathophysiology of autoimmune myositis. Upregulation of type 1 IFN stimulated genes (an…
  • Abstract Number: 2047 • ACR Convergence 2023

    Safety of Baricitinib for COVID-19 Related Hyperinflammation in Pediatric Patients: A Large Tertiary Care Center Experience

    Meredith Rae1, Jessica Nguyen2, Marietta DeGuzman3, Catherine Foster1, Flor Munoz1 and Eyal Muscal4, 1Baylor College of Medicine, Texas Children's Hospital, Houston, TX, 2Baylor College of Medicine, Manvel, TX, 3Baylor College of Medicine / Texas Children's Hospital, Houston, TX, 4Division of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, TX

    Background/Purpose: A small proportion of children with acute COVID-19 experienced life-threatening hyperinflammation. It has been proposed that an innate immune recognition of viral RNA triggers…
  • 1
  • 2
  • 3
  • …
  • 17
  • Next Page »
Search Again »

Didn't find what you were looking for? Try the Advanced Search »

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology